Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of SHR1459 Old vs New Formulation in Healthy Chinese Volunteers
NCT04395053Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jun 2020
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of edralbrutinib in B cell malignancies and autoimmune diseases (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve. Started Jun 2020; status: completed.
02
Drugs
edralbrutinib
03
Conditions
B cell malignanciesautoimmune diseases
Beyond the preview
Go deeper on NCT04395053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395053.